

# Equity Research Desk

# Stock SCREENER

20 JUL 2022

## Fundamental Players

### Criteria:

- Cash flow Margin – The stocks with more than 15% of Cash Flow Margin. (Cash Flow Margin: Operating Cash flow/Net revenue)
- 5Y Sales CAGR – The Stocks with more than 7% of Sales CAGR for the past 5 Years.
- 5Y Avg. NPM – The stocks with more than 15% of Average Net profit Margin for the past 5 years.

25th Apr'22 to 19th Jul'22	
Constituents	Returns
Nifty	-4%
Previous Screener	-12%

➤ The previous screener on Fundamental Players has underperformed the Nifty by 8%.

**New Entry** – ITC, GLAXO, GLAND

**Exit** – CAMS, LALPATHLAB, UTIAMC

Name	Sub-Sector	MCap	Cash Flow Margin	5Y Sales CAGR	5Y Avg. NPM	5Y Avg. RoE
HDFC AMC Ltd	Asset Management	41200	51.5%	8.9%	51.8%	33.3%
CDSL	Depositories	11577	48.1%	26.7%	46.1%	17.9%
Eris Lifesciences Ltd	Pharmaceuticals	9129	30.8%	12.1%	29.6%	34.4%
Divi's Laboratories Ltd	Labs & Life Sciences	99637	27.7%	17.0%	26.8%	20.3%
ITC Ltd	Diversified	364008	25.2%	7.0%	25.7%	23.0%
P & G Hygiene and Healthcare Ltd	FMCG – Personal	45692	23.9%	8.9%	15.9%	51.3%
Vinati Organics Ltd	Specialty Chemicals	21587	22.3%	20.7%	24.5%	24.2%
Clean Science and Tech Ltd	Specialty Chemicals	17959	17.8%	29.7%	29.1%	39.5%
GlaxoSmithKline Pharma Ltd	Pharmaceuticals	25624	17.2%	9.2%	15.1%	29.3%
Gland Pharma Ltd	Pharmaceuticals	40334	16.8%	25.0%	24.4%	19.6%

- **HDFC AMC Ltd** – HDFC AMC Ltd – HDFC Asset Management Company (HDFC AMC) is Promoted by HDFC Ltd (52.60% of share), is one of the largest AMCs in India with a total assets under management (AUM) of Rs.4,07,553 Cr. as of Mar 2022 and a QAAUM (Quarterly average AUM) market share of 11.3% for the quarter ended March 31, 2022.
- **CDSL** – Central Depository Services (CDSL) is one of two depositories in India and the only one to be listed. Despite being a late entrant in the market, CDSL has been gaining market share from NSDL. Today it has become a market leader with 64% market share.
- **Eris LifeSciences Ltd** – Eris Lifesciences Ltd is the only publicly listed Indian pharmaceutical company with a pure-play domestic branded formulations business model. Established in 2007, Eris is by far the youngest company in the IPM Top-25.
- **Divi's Laboratories Ltd.** – The Company has a market presence in 100+ countries and ~17,000 employees and is one of the leading pharmaceutical companies in the world. The company has a strong financial record with 17% Revenue CAGR and 19% PAT CAGR over the past 10 years.
- **ITC Ltd** – Established in 1910, ITC is the largest cigarette manufacturer and seller in the country. ITC operates in five business segments at present – FMCG Cigarettes, FMCG Others, Hotels, Paperboards, Paper and Packaging, and Agri Business.
- **P&G Hygiene and Healthcare Ltd** – P & G Hygiene and HealthCare Ltd. is engaged in the manufacturing and selling of famous branded FMCGs like Pampers, Ariel, Tide, Head & Shoulders, Pantene, Oral B. Whisper, Vicks & Old Spice, etc.
- **Vinati Organics Ltd.** – The company ranked #1 manufacturer of IBB and ATBS with a global market share of 65% for both the chemical products. VOL is the only backward integrated manufacturer of ATBS and butyl phenols with its own Isobutylene (IB) manufacturing unit which makes its operations more cost efficient.
- **Clean Science and Tech. Ltd** – The company manufactures functionally critical Speciality Chemicals, Pharmaceutical Intermediates and FMCG Chemicals. The differentiation in the process manufacturing between Clean science and peers assisted company to offer products at competitive price and thereby helped it gain meaningful market share across its product portfolio.
- **GSK Pharma Ltd** – GlaxoSmithKline Pharmaceutical is a part of GlaxoSmithKline plc (GSK), a British multinational pharmaceutical company headquartered in London. The company is market leader in therapy areas of anti-infectives, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases.
- **Gland Pharma Ltd** – Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets.

**Warm Regards,**  
**Equity Research Desk**

**Abeshak C V**

**Disclaimer:** Wealth India Financial Services Pvt. Ltd is registered under the SEBI (Research Analyst) Regulations, 2014 (SEBI Regulations) as a Research Analyst vide Registration No. INH200000394.

The analyst for this report certifies that all the views expressed in this report accurately reflect his / her personal views about the subject company or companies, and its / their securities. No part of his / her compensation was / is / will be, directly / indirectly related to specific recommendations or views expressed in this report. This material is for the personal information of the authorized recipient, and no action is solicited on the basis of this. It is not to be construed as an offer to sell, or the solicitation of an offer to buy any security, in any jurisdiction, where such an offer or solicitation would be illegal.

We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable, though its accuracy or completeness cannot be guaranteed. Neither Wealth India Financial Services Pvt. Ltd., nor any person connected with it, accepts any liability arising from the use of this document. The recipients of this material should rely on their own investigations and take their own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance.

We and our affiliates, officers, directors, and employees worldwide:  
Do not have any financial interest in the subject company / companies in this report;  
Do not have any actual / beneficial ownership of one per cent or more in the company / companies mentioned in this document, or in its securities at the end of the month immediately preceding the date of publication of the research report, or the date of public appearance;  
Do not have any other material conflict of interest at the time of publication of the research report, or at the time of public appearance;  
Have not received any compensation from the subject company / companies in the past 12 months;  
Have not managed or co-managed the public offering of securities for the subject company / companies in the past 12 months;  
Have not received any compensation for investment banking, or merchant banking, or brokerage services from the subject company / companies in the past 12 months;  
Have not served as an officer, director, or employee of the subject company;  
Have not been engaged in market making activity for the subject company;  
This document is not for public distribution. It has been furnished to you solely for your information, and must not be reproduced or redistributed to any other person.

You are receiving this mail because you are a registered user at [www.FundsIndia.com](http://www.FundsIndia.com).  
Our mailing address is:  
Uttam Building, Third Floor,  
No. 38 & 39, Whites Road, Royapettah, Chennai – 600014

Copyright (C) 2022 Wealth India Financial Services All rights reserved.